Search Results - "Marrer‐Berger, Estelle"

Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody by Belli, Sara, Amann, Maria, Hutchinson, Lucy, Pousse, Laurène, Abdolzade‐Bavil, Afsaneh, Justies, Nicole, Jacobsen, Bjoern, Ploix, Corinne, Tselempi, Eleni, Tosevski, Vinko, Koll, Hans, Schnetzler, Gabriel, Boetsch, Christophe, Marrer‐Berger, Estelle

“…The multifaceted IL‐2/IL‐2R biology and its modulation by promising therapeutic agents are highly relevant topics in the cancer immunotherapy field. A novel…”
Get full text

The physiological interactome of TCR-like antibody therapeutics in human tissues by Marrer-Berger, Estelle, Nicastri, Annalisa, Augustin, Angelique, Kramar, Vesna, Liao, Hanqing, Hanisch, Lydia Jasmin, Carpy, Alejandro, Weinzierl, Tina, Durr, Evelyne, Schaub, Nathalie, Nudischer, Ramona, Ortiz-Franyuti, Daniela, Breous-Nystrom, Ekaterina, Stucki, Janick, Hobi, Nina, Raggi, Giulia, Cabon, Lauriane, Lezan, Emmanuelle, Umaña, Pablo, Woodhouse, Isaac, Bujotzek, Alexander, Klein, Christian, Ternette, Nicola

“…Selective binding of TCR-like antibodies that target a single tumour-specific peptide antigen presented by human leukocyte antigens (HLA) is the absolute…”
Get full text

Abstract 6135: Tumor-bearing non-human primates: An unrivaled model for translational cancer immunology research by Ceppi, Maurizio, Hettich, Michael, Teichgräber, Volker, Driessen, Wouter, Tuerck, Dietrich, Marrer-Berger, Estelle, Evers, Stefan, Crameri, Flavio, Gomes, Bruno, Bachl, Jürgen, Klein, Christian, Claus, Christina, Amann, Maria, Krieter, Oliver, Dugan, Greg, Caudell, David, Grayson, Jason, Kiran, Sai Kumar Solingapuram, Cline, Mark

“…Abstract The translatability of mouse models for the clinical development of cancer immunotherapies remains limited because of substantial differences between…”
Get full text

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies by Leclercq, Gabrielle, Haegel, Hélène, Schneider, Anneliese, Giusti, Anna Maria, Marrer-Berger, Estelle, Boetsch, Christophe, Walz, Antje-Christine, Pulko, Vesna, Sam, Johannes, Challier, John, Ferlini, Cristiano, Odermatt, Alex, Umaña, Pablo, Bacac, Marina, Klein, Christian

“…BackgroundT cell engagers are bispecific antibodies recognizing, with one moiety, the CD3ε chain of the T cell receptor and, with the other moiety, specific…”
Get full text

Patient-derived micro-organospheres enable clinical precision oncology by Ding, Shengli, Hsu, Carolyn, Wang, Zhaohui, Natesh, Naveen R., Millen, Rosemary, Negrete, Marcos, Giroux, Nicholas, Rivera, Grecia O., Dohlman, Anders, Bose, Shree, Rotstein, Tomer, Spiller, Kassandra, Yeung, Athena, Sun, Zhiguo, Jiang, Chongming, Xi, Rui, Wilkin, Benjamin, Randon, Peggy M., Williamson, Ian, Nelson, Daniel A., Delubac, Daniel, Oh, Sehwa, Rupprecht, Gabrielle, Isaacs, James, Jia, Jingquan, Chen, Chao, Shen, John Paul, Kopetz, Scott, McCall, Shannon, Smith, Amber, Gjorevski, Nikolche, Walz, Antje-Christine, Antonia, Scott, Marrer-Berger, Estelle, Clevers, Hans, Hsu, David, Shen, Xiling

“…Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown to model clinical response to cancer therapy. However, it remains…”
Get full text

Cytokine Release Syndrome By T-cell-Redirecting Therapies: Can We Predict and Modulate Patient Risk? by Van De Vyver, Arthur J, Marrer-Berger, Estelle, Wang, Ken, Lehr, Thorsten, Walz, Antje-Christine

“…T-cell-redirecting therapies are promising new therapeutic options in the field of cancer immunotherapy, but the development of these modalities is…”
Get full text

Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies by Kroll, Katharina T, Mata, Mariana M, Homan, Kimberly A, Micallef, Virginie, Carpy, Alejandro, Hiratsuka, Ken, Morizane, Ryuji, Moisan, Annie, Gubler, Marcel, Walz, Antje-Christine, Marrer-Berger, Estelle, Lewis, Jennifer A

“…T cell bispecific antibodies (TCBs) are the focus of intense development for cancer immunotherapy. Recently, peptide-MHC (major histocompatibility…”
Get full text

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody by Augsberger, Christian, Hänel, Gerulf, Xu, Wei, Pulko, Vesna, Hanisch, Lydia Jasmin, Augustin, Angelique, Challier, John, Hunt, Katharina, Vick, Binje, Rovatti, Pier Eduardo, Krupka, Christina, Rothe, Maurine, Schönle, Anne, Sam, Johannes, Lezan, Emmanuelle, Ducret, Axel, Ortiz-Franyuti, Daniela, Walz, Antje-Christine, Benz, Jörg, Bujotzek, Alexander, Lichtenegger, Felix S., Gassner, Christian, Carpy, Alejandro, Lyamichev, Victor, Patel, Jigar, Konstandin, Nikola, Tunger, Antje, Schmitz, Marc, von Bergwelt-Baildon, Michael, Spiekermann, Karsten, Vago, Luca, Jeremias, Irmela, Marrer-Berger, Estelle, Umaña, Pablo, Klein, Christian, Subklewe, Marion

“…Antibody-based immunotherapy is a promising strategy for targeting chemoresistant leukemic cells. However, classical antibody-based approaches are restricted…”
Get full text

Micro-organospheres retain patient tumor microenvironment for precision immuno-oncology by Ding, Shengli, Natesh, Naveen R., Spiller, Kassandra, Xi, Rui, Nelson, Daniel, Gjorevski, Nikolche, Walz, Antje, Marrer-Berger, Estelle, Clevers, Hans, Hsu, Shiaowen David, Shen, Xiling

“…2573 Background: Current patient-derived organoid (PDO) models are largely devoid of immune components. We developed a precision microfluidic and membrane…”
Get full text

CD25-T reg -depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity by Solomon, Isabelle, Amann, Maria, Goubier, Anne, Arce Vargas, Frederick, Zervas, Dimitrios, Qing, Chen, Henry, Jake Y, Ghorani, Ehsan, Akarca, Ayse U, Marafioti, Teresa, Śledzińska, Anna, Werner Sunderland, Mariana, Franz Demane, Dafne, Clancy, Joanne Ruth, Georgiou, Andrew, Salimu, Josephine, Merchiers, Pascal, Brown, Mark Adrian, Flury, Reto, Eckmann, Jan, Murgia, Claudio, Sam, Johannes, Jacobsen, Bjoern, Marrer-Berger, Estelle, Boetsch, Christophe, Belli, Sara, Leibrock, Lea, Benz, Joerg, Koll, Hans, Sutmuller, Roger, Peggs, Karl S, Quezada, Sergio A

“…Intratumoral regulatory T cell (Treg) abundance associates with diminished anti-tumor immunity and poor prognosis in human cancers. Recent work demonstrates…”
Get full text

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity by Solomon, Isabelle, Amann, Maria, Goubier, Anne, Arce Vargas, Frederick, Zervas, Dimitrios, Qing, Chen, Henry, Jake Y., Ghorani, Ehsan, Akarca, Ayse U., Marafioti, Teresa, Śledzińska, Anna, Werner Sunderland, Mariana, Franz Demane, Dafne, Clancy, Joanne Ruth, Georgiou, Andrew, Salimu, Josephine, Merchiers, Pascal, Brown, Mark Adrian, Flury, Reto, Eckmann, Jan, Murgia, Claudio, Sam, Johannes, Jacobsen, Bjoern, Marrer-Berger, Estelle, Boetsch, Christophe, Belli, Sara, Leibrock, Lea, Benz, Joerg, Koll, Hans, Sutmuller, Roger, Peggs, Karl S., Quezada, Sergio A.

“…Intratumoral regulatory T cell (Treg) abundance associates with diminished anti-tumor immunity and poor prognosis in human cancers. Recent work demonstrates…”
Get full text

Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment by Brennan, Frank R., Cavagnaro, Joy, McKeever, Kathleen, Ryan, Patricia C., Schutten, Melissa M., Vahle, John, Weinbauer, Gerhard F., Marrer-Berger, Estelle, Black, Lauren E.

“…Monoclonal antibodies (mAbs) are improving the quality of life for patients suffering from serious diseases due to their high specificity for their target and…”
Get full text

Abstract 4553: The CD25 antibody RG6292 selectively depletes Tregs while preserving IL-2 signaling and CTL activity for tumor control by Amann, Maria, Schnetzler, Gabriel, Theresa, Kolben, Solomon, Isabelle, Boetsch, Christophe, Marrer-Berger, Estelle, Flury, Reto, Murgia, Claudio, Karanikas, Vaios, Sam, Johannes, Sutmuller, Roger, Eckmann, Jan, Koll, Hans, Belli, Sara, Vargas, Frederic Arce, Zervas, Dimitrios, Qing, Chen, Brown, Mark A., Salimu, Josephine, Goubier, Anne, Neumann, Sebastian, Peggs, Karl S., Quezada, Sergio A.

“…Abstract Despite the advances in cancer immunotherapy, in particular in the field of checkpoint inhibitors (CPI), many patients fail to respond (primary…”
Get full text

Transforming preclinical assessment to meet clinical relevance with advanced models by Breous-Nystrom, Ekaterina, Kronenberg, Sven, Marrer-Berger, Estelle, Roth, Adrian, Lave, Thierry, Singer, Thomas

“…The advances in the immunotherapy field in the last decade have enabled efficient treatment of previously intractable cancers. These advances have also exposed…”
Get full text

Gut Microbiota Is Associated with Onset and Severity of Type 1 Diabetes in Nonobese Diabetic Mice Treated with Anti-PD-1 by Patel, Shriram, Becker, Eugenia, Ploix, Corinne, Steiner, Guido, Scepanovic, Petar, Fueth, Matthias, de Vera Mudry, Maria Cristina, Eichinger-Chapelon, Anne, Marrer-Berger, Estelle, Claesson, Marcus J

“…Our bodies are home to individual-specific microbial ecosystems that have recently been found to be modified by cancer immunotherapies. The interaction between…”
Get full text

653 Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release by Leclercq, Gabrielle, Haegel, Helene, Schneider, Anneliese, Berger, Estelle Marrer, Walz, Antje, Boetsch, Christophe, Pulko, Vesna, Ferlini, Cristiano, Klein, Christian

“…BackgroundT cell bispecific antibodies (TCBs) are extremely potent T cell engagers, harboring a 2+1 format with one binder to the CD3ε chain and two binders to…”
Get full text